Recent insights into the molecular mechanisms of the NLRP3 inflammasome activation
- PMID: 27508077
- PMCID: PMC4963208
- DOI: 10.12688/f1000research.8614.1
Recent insights into the molecular mechanisms of the NLRP3 inflammasome activation
Abstract
Inflammasomes are high-molecular-weight protein complexes that are formed in the cytosolic compartment in response to danger- or pathogen-associated molecular patterns. These complexes enable activation of an inflammatory protease caspase-1, leading to a cell death process called pyroptosis and to proteolytic cleavage and release of pro-inflammatory cytokines interleukin (IL)-1β and IL-18. Along with caspase-1, inflammasome components include an adaptor protein, ASC, and a sensor protein, which triggers the inflammasome assembly in response to a danger signal. The inflammasome sensor proteins are pattern recognition receptors belonging either to the NOD-like receptor (NLR) or to the AIM2-like receptor family. While the molecular agonists that induce inflammasome formation by AIM2 and by several other NLRs have been identified, it is not well understood how the NLR family member NLRP3 is activated. Given that NLRP3 activation is relevant to a range of human pathological conditions, significant attempts are being made to elucidate the molecular mechanism of this process. In this review, we summarize the current knowledge on the molecular events that lead to activation of the NLRP3 inflammasome in response to a range of K (+) efflux-inducing danger signals. We also comment on the reported involvement of cytosolic Ca (2+) fluxes on NLRP3 activation. We outline the recent advances in research on the physiological and pharmacological mechanisms of regulation of NLRP3 responses, and we point to several open questions regarding the current model of NLRP3 activation.
Keywords: Inflammasome; NLRP3; autoinflammatory disease; pyroptosis.
Conflict of interest statement
No competing interests were disclosed.
Figures



Similar articles
-
Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux.Eur J Immunol. 2015 Oct;45(10):2927-36. doi: 10.1002/eji.201545772. Epub 2015 Aug 6. Eur J Immunol. 2015. PMID: 26173909
-
The pathological role of NLRs and AIM2 inflammasome-mediated pyroptosis in damaged blood-brain barrier after traumatic brain injury.Brain Res. 2018 Oct 15;1697:10-20. doi: 10.1016/j.brainres.2018.06.008. Epub 2018 Jun 8. Brain Res. 2018. PMID: 29886252
-
Caspase-1 autoproteolysis is differentially required for NLRP1b and NLRP3 inflammasome function.Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17254-9. doi: 10.1073/pnas.1415756111. Epub 2014 Nov 17. Proc Natl Acad Sci U S A. 2014. PMID: 25404286 Free PMC article.
-
Regulation of NLRP3 Inflammasome by Phosphorylation.Front Immunol. 2018 Oct 8;9:2305. doi: 10.3389/fimmu.2018.02305. eCollection 2018. Front Immunol. 2018. PMID: 30349539 Free PMC article. Review.
-
NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases.Redox Biol. 2015;4:296-307. doi: 10.1016/j.redox.2015.01.008. Epub 2015 Jan 14. Redox Biol. 2015. PMID: 25625584 Free PMC article. Review.
Cited by
-
Caspase-1 inflammasome activity in patients with Staphylococcus aureus bacteremia.Microbiol Immunol. 2019 Dec;63(12):487-499. doi: 10.1111/1348-0421.12738. Epub 2019 Oct 16. Microbiol Immunol. 2019. PMID: 31403210 Free PMC article.
-
Ulinastatin inhibits NLRP3-induced apoptosis in a PD cell model.Ann Transl Med. 2021 Jun;9(11):924. doi: 10.21037/atm-21-1882. Ann Transl Med. 2021. PMID: 34350239 Free PMC article.
-
NLRC and NLRX gene family mRNA expression and prognostic value in hepatocellular carcinoma.Cancer Med. 2017 Nov;6(11):2660-2672. doi: 10.1002/cam4.1202. Epub 2017 Sep 29. Cancer Med. 2017. PMID: 28960882 Free PMC article.
-
New Insights on NLRP3 Inflammasome: Mechanisms of Activation, Inhibition, and Epigenetic Regulation.J Neuroimmune Pharmacol. 2024 Feb 29;19(1):7. doi: 10.1007/s11481-024-10101-5. J Neuroimmune Pharmacol. 2024. PMID: 38421496 Free PMC article. Review.
-
NLRP3 inflammasome: The rising star in cardiovascular diseases.Front Cardiovasc Med. 2022 Sep 20;9:927061. doi: 10.3389/fcvm.2022.927061. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36204568 Free PMC article. Review.
References
-
- Perregaux D, Barberia J, Lanzetti AJ, et al. : IL-1 beta maturation: evidence that mature cytokine formation can be induced specifically by nigericin. J Immunol. 1992;149(4):1294–303. - PubMed
-
- Perregaux D, Gabel CA: Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem. 1994;269(21):15195–203. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous